Lane Judge
Family · Monroe, MINPI 1528587615
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 89.9% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2023 at $11,934 and has fallen 92.7% since, to $873 in 2025. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 492 payments — averaging $78.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$35K
- Dexcom, Inc.$2K
- Lilly USA, LLC$502
- Medtronic$270
- Boehringer Ingelheim$229
- Abbott$180
- plus $1K from 26 others
What the payments were for
- Consulting fees$9,73525%
- Speaking & faculty fees$14,41637%
- Travel & lodging$7,42719%
- Food & beverage$7,21119%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 193 | $34,870 |
| Dexcom, Inc. | 157 | $1,546 |
| Lilly USA, LLC | 30 | $502 |
| Medtronic | 18 | $270 |
| Boehringer Ingelheim | 13 | $229 |
| Abbott | 10 | $180 |
| Novartis | 9 | $155 |
| Antares Pharma, Inc. | 7 | $119 |
| Amgen | 6 | $97 |
| AstraZeneca | 7 | $94 |
| Mannkind Corporation | 4 | $73 |
| Tandem Diabetes Care, Inc. | 5 | $59 |
| Xeris Pharmaceuticals, Inc. | 4 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $58 |
| Nevro Corp. | 2 | $58 |
| Insulet Corporation | 3 | $57 |
| Verity Pharmaceuticals Inc. | 3 | $53 |
| AbbVie | 3 | $45 |
| Amphastar Pharmaceuticals, Inc. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Cequr Corporation | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Lifescan, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| BD | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$14,354
- Ozempic$4,021
- DEXCOM G6 TRANSMITTER$122
How this compares
$38,802 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 367 | $479,634 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 67 | $118,032 |
| TrulicityDulaglutide | 72 | $117,047 |
| MounjaroTirzepatide | 88 | $110,606 |
| JardianceEmpagliflozin | 58 | $54,340 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $40,517 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 150 | $37,445 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $36,470 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $35,074 |
| Novolog FlexpenInsulin Aspart | 57 | $33,996 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $28,839 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $25,831 |
| Humalog Kwikpen U-100Insulin Lispro | 56 | $25,633 |
| JanuviaSitagliptin Phosphate | 18 | $20,824 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $17,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $34,870 | $486,294379 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $502 | $232,546182 claims |
| Boehringer IngelheimJardiance | $229 | $54,34058 claims |
| MerckJanuvia | $19 | $20,82418 claims |
| AstraZenecaFarxiga | $94 | $15,16015 claims |
| Sanofi-aventis U.S. LLCLantus | $13 | $4,50712 claims |
| AbbVieSynthroid, Armour Thyroid | $45 | $4,14161 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $58 | $3,291315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Monroe
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.